BRIEF-Argenx Says Phase 3 ALKIVIA Study Met Its Primary Endpoint

2

Oct 19 (Reuters) – argenx SE: * TO PRESENT PHASE 3 ALKIVIA RESULTS IN AUTOIMMUNE MYOSITIS AS A LATE-BREAKING ORAL PRESENTATION AT ACR CONVERGENCE 2026 * ALKIVIA PROVIDES FIRST PHASE 3 EVIDENCE THAT

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)